GLP-3 RTA Triple G 30mg multi agonist peptide blend. Research grade formulation with consistent composition and secure packaging.
Pack Size Selected: Single Pack
Pay with Interac e-Transfer or Crypto
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
GLP-3 RTA (Triple G) is a triple incretin receptor agonist simultaneously targeting glucagon like peptide 1 (GLP-1), glucose dependent insulinotropic polypeptide (GIP), and glucagon receptors, the most advanced incretin based research compound in CSD’s metabolic peptide range. Hudson Science’s 30mg formulation delivers the lowest concentration presentation across CSD’s full GLP-3 RTA range as a lyophilized vial, providing the most accessible entry point into triple incretin agonist research and the most granular dose response evaluation capability at the lower end of the concentration spectrum.
The 30mg concentration serves a distinct research purpose within the GLP-3 RTA family. For researchers initiating triple incretin agonist protocols, the 30mg format minimizes initial compound commitment while establishing baseline pharmacological response data before progressing to higher concentration presentations. For dose response study designs examining triple incretin receptor co activation across a broad concentration range, the 30mg format provides the lowest reference point in a series that extends through the iLab Pharma 40mg, Hudson Science 50mg, and Hudson Science 60mg variants; enabling comprehensive dose escalation research within the GLP-3 RTA compound family from a single verified Canadian supplier.
The triple receptor mechanism remains consistent across all GLP-3 RTA presentations regardless of concentration or manufacturer. GLP-1 receptor activation drives glucose dependent insulin secretion, glucagon suppression, and central nervous system satiety signaling. GIP receptor activation contributes complementary insulinotropic activity alongside adipose tissue metabolic and bone turnover research dimensions. Glucagon receptor co activation adds hepatic glucose output regulation, thermogenic energy expenditure stimulation, and lipolytic activity. A third distinct pathway producing a synergistic metabolic response that distinguishes triple incretin agonism from the dual GIP/GLP-1 mechanism of CSD’s GLP-2 TZ and GLP-2 TRZ listings.
Hudson Science formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and Hudson Science’s GLP-3 RTA 30mg meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.
Commonly researched alongside dual incretin agonist compounds in comparative receptor pathway and metabolic activity studies. Browse CSD’s full peptide range for complete sourcing.
been body building training for 15 years. never been avle to follow through with a proper cut and tried everything. lost 40lbs with this and now I'm huge AND lean. priceless
![GLP-3 RTA [Triple G] - 30mg](https://www.canadasteroiddepot.is/wp-content/uploads/2026/03/HUD-GLP3-30-600x600.png)
![Epitalon - 10mg [Longevity]](https://www.canadasteroiddepot.is/wp-content/uploads/2023/11/img_1457-2048x2048-1-300x300.png)
![GLP-3 RTA [Triple G] - 30mg](https://www.canadasteroiddepot.is/wp-content/uploads/2026/03/HUD-GLP3-30-100x100.png.webp)